WO2024084441 - COMBINATION HIV VACCINE
National phase entry is expected:
Publication Number
WO/2024/084441
Publication Date
25.04.2024
International Application No.
PCT/IB2023/060589
International Filing Date
19.10.2023
Title **
[English]
COMBINATION HIV VACCINE
[French]
VACCIN COMBINÉ CONTRE LE VIH
Applicants **
AELIX THERAPEUTICS, S.L.
Inventors
BRANDER, Christian
PUJADAS, Beatriz Mothe
SANDERS, Rogier
SHATTOCK, Robin
Priority Data
63/380,113
19.10.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2477 | |
| EPO | Filing, Examination, Granting | 14073 | |
| Japan | Filing, Examination, Granting | 2515 | |
| South Korea | Filing, Examination, Granting | 2641 | |
| USA | Filing, Examination, Granting | 5740 |
Total:
27,446
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides methods, compositions, and kits for the treatment or prevention of an HIV infection in a human having or at risk of having HIV, comprising the combination of the HTI immunogen and at least one stable soluble HIV-1 envelope glycoprotein trimer mimic, such as ConM SOSIP.v7 gp140 trimer.[French]
La présente divulgation concerne des méthodes, des compositions et des kits pour le traitement ou la prévention d'une infection par le VIH chez un être humain ayant le VIH ou présentant un risque d'avoir le VIH, comprenant la combinaison de l'immunogène HTI et d'au moins un mimétique de trimère de glycoprotéine d'enveloppe du VIH-1 soluble stable, tel que le trimère de la gp140 de ConM SOSIP.v7.